Relacorilant shows promise for ovarian cancer treatment

Corcept Therapeutics (CORT) announced positive Phase 3 ROSELLA trial results showing that relacorilant combined with nab-paclitaxel significantly improved outcomes for patients with platinum-resistant ovarian cancer, reducing the risk of disease progression by 30% and the risk of death by 31% compared to nab-paclitaxel alone. The combination therapy also demonstrated a well-tolerated safety profile. Corcept is expediting regulatory applications in the U.S. and Europe, with analysts setting price targets between $131 and $145 despite the stock currently trading above its fair value.

Analysis

Corcept Therapeutics (NASDAQ: CORT) has announced compelling Phase 3 ROSELLA trial results for relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer, demonstrating a 30% reduction in disease progression risk and a 31% decrease in death risk based on interim analysis, with median progression-free survival improving to 6.5 months and median overall survival to 16.0 months, respectively. This positive clinical outcome, coupled with a well-tolerated safety profile, positions relacorilant as a potential new standard of care. Despite this significant clinical advancement and a robust 98.36% gross profit margin, the company reported mixed Q1 2025 results: earnings per share of $0.17 surpassed analyst expectations of $0.14, but revenue of $157.2 million fell short of the anticipated $177.9 million, attributed to now-resolved pharmacy vendor issues. Management has maintained its 2025 revenue guidance of $900-$950 million, noting Korlym prescriptions nearly doubled even with a 13% average price decrease due to generic transition. The stock has delivered a 157% return over the past year and currently trades above InvestingPro's assessed Fair Value, though analysts maintain price targets between $131 (Piper Sandler, Overweight) and $145 (H.C. Wainwright, Buy). Corcept is expediting regulatory applications for relacorilant, with an FDA decision on its New Drug Application for hypercortisolism and ovarian cancer anticipated by December 2025, representing a key upcoming catalyst.

Key Decisions for Investors

• Investors should weigh the significant clinical de-risking from the positive ROSELLA trial results and the potential market for relacorilant against Corcept's current valuation, which InvestingPro suggests is above fair value, despite strong analyst price targets.
• Closely monitor the company's progress towards regulatory approval for relacorilant in both the U.S. and Europe, with the FDA decision expected by December 2025 being a critical catalyst that could substantially impact the stock.
• Assess management's ability to meet the reaffirmed 2025 revenue guidance of $900-$950 million, considering the Q1 revenue miss, the ongoing dynamics of the Korlym franchise, and the operational improvements with its pharmacy vendor.